Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 1;3(1):114-118.
doi: 10.1016/j.jacbts.2017.12.001. eCollection 2018 Feb.

Advances in Cardiovascular Care: How to Stimulate Innovation While Controlling Cost

William S Weintraub  1 , Kelvin H Lee  2
Affiliations
Review

Advances in Cardiovascular Care: How to Stimulate Innovation While Controlling Cost

William S Weintraub et al. JACC Basic Transl Sci. .

Abstract

There is increasing concern over the cost of pharmaceuticals. An approach to assessing the value of new pharmaceuticals compared with previous standards is cost-effectiveness analysis. Although cost-effectiveness analysis may not be able to directly answer societal questions about new drugs, it can make the underlying assumptions clear. As new pharmaceuticals are becoming more expensive, the issues concerning societal willingness-to-pay become more critical. This is especially true of biologics, where the cost of manufacture is much higher than for small molecules. Indeed, new biologics have gone from being unusual to dominating the market for new pharmaceuticals. Efficiency in manufacturing will need to be gradually addressed to make these life-saving therapies more widely available.

Keywords: biologics; cost-effectiveness; innovation.

PubMed Disclaimer

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Nabel E.G., Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366:54–63. - PubMed
    1. Ford E.S., Ajani U.A., Croft J.B. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–2398. - PubMed
    1. Weintraub W.S., Daniels S.R., Burke L.E., for the American Heart Association Advocacy Coordinating Committee. Council on Cardiovascular Disease in the Young. Council on the Kidney in Cardiovascular Disease. Council on Epidemiology and Prevention. Council on Cardiovascular Nursing. Council on Arteriosclerosis. Thrombosis and Vascular Biology. Council on Clinical Cardiology, and Stroke Council Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011;124:967–990. - PubMed
    1. Weintraub W.S., Gidding S.S. PCSK9 inhibitors: a technology worth paying for? Pharmacoeconomics. 2016;34:217–220. - PMC - PubMed
    1. Hlatky M.A., Kazi D.S. PCSK9 inhibitors: economics and policy. J Am Coll Cardiol. 2017;70:2677–2687. - PubMed

LinkOut - more resources